General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Bio-Path (BPTH) to Release Quarterly Earnings on Wednesday | news.google.com • |
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study | zacks.com • |
Why Is Bio-Path (BPTH) Stock Up 89% Today? | investorplace.com • |
Bio-Path Holdings shares sink 6% after deal for at-the-market offering | marketwatch.com • |
Bio-Path Holdings Inc. (BPTH) Q4 2023 Earnings Call Transcript | seekingalpha.com • |
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024 | globenewswire.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-15 | 2024-03 | -4.54 | -4.88 | -0.34 | -7.49% |
2024-03-08 | 2023-12 | 0 | N/A | N/A | N/A |
2023-11-15 | 2023-09 | -6.8 | -6.4 | 0.4 | 5.88% |
2023-08-15 | 2023-06 | -10.4 | -10.6 | -0.2 | -1.92% |
2023-05-12 | 2023-03 | -9 | -13.2 | -4.2 | -46.67% |
2023-03-31 | 2022-12 | -9 | -10.6 | -1.6 | -17.78% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2022-05-18 | HC Wainwright & Co. | Upgrade | Buy | |
2021-03-10 | Roth Capital | Upgrade | Buy | |
2020-11-15 | HC Wainwright & Co. | Upgrade | Buy | |
2020-08-16 | HC Wainwright & Co. | Upgrade | Buy | |
2020-05-17 | HC Wainwright & Co. | Upgrade | Buy | |
2019-12-01 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2019-01-17 | ARMISTICE CAPITAL L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
2015-07-12 | GARRISON MICHAEL J | Director | 908.33K | Purchase |
2009-12-01 | GARRISON THOMAS E | Director | 2.51M | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 239.09K | 425.57K | 2.09% |
2023-06-29 | Geode Capital Management, LLC | 67.37K | 119.92K | 0.59% |
2023-06-29 | Blackrock Inc. | 48.47K | 86.27K | 0.42% |
2023-06-29 | Renaissance Technologies, LLC | 21.40K | 38.09K | 0.19% |
2023-06-29 | Northern Trust Corporation | 17.71K | 31.53K | 0.15% |
2023-06-29 | State Street Corporation | 13.03K | 23.20K | 0.11% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 121.08K | 215.53K | 1.06% |
2023-06-29 | Vanguard Extended Market Index Fund | 108.93K | 193.89K | 0.95% |
2023-05-30 | Fidelity Extended Market Index Fund | 35.71K | 58.92K | 0.31% |
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 15.10K | 24.92K | 0.13% |
2023-05-30 | Fidelity Series Total Market Index Fund | 9.68K | 15.98K | 0.08% |
2023-05-30 | Fidelity Total Market Index Fund | 3.39K | 5.60K | 0.03% |
Split | Date |
---|---|
1 : 20 | 2024-02-23 |
1 : 20 | 2019-01-18 |
1 : 10 | 2018-02-09 |
ecent Corporate Highlights
Announced Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia. In August, Bio-Path reported positive interim data from Stage 2 of the Company's Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML). Prexigebersen continues to be well-tolerated and has now shown compelling efficacy results in two reporting cohorts including evaluable newly diagnosed AML patients and evaluable refractory/relapsed AML patients, which exceed outcomes with combination treatment of decitabine and venetoclax.
ecent Corporate Highlights
Announced Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia. In August, Bio-Path reported positive interim data from Stage 2 of the Company's Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML). Prexigebersen continues to be well-tolerated and has now shown compelling efficacy results in two reporting cohorts including evaluable newly diagnosed AML patients and evaluable refractory/relapsed AML patients, which exceed outcomes with combination treatment of decitabine and venetoclax.
Buy $TYME. Hear me out. New ceo and 100m share offering. Same week they patent covid oral cure. cup and handle is being formed. Reason for red day. Past 3.18 this will blast multiples. Please do your dd and thank me later.
P.s. the new ceo of TYME is the one the ceo that sold the current cure to Pfizer. So........
Buy $TYME. Hear me out. New ceo and 100m share offering. Same week they patent covid oral cure. cup and handle is being formed. Reason for red day. Past 3.18 this will blast multiples. Please do your dad and thank me later.
P.s. the new ceo of TYME is the one the ceo that sold the current cure to Pfizer. So........
$ICON only 11M float. Big brands under the umbrella. Umbro is in Walmart. New licensing agreement for MUDD. Trading under $1.00